Avian Influenza A H7N9 Neuraminide Antilichaam

Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA (1) . Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found (2) . These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. H7N9 bird flu is the newest atypical influenza virus infection that has just been reported since early 2013. The emergence of this new strain occurred in China and has become the present focus for possible worldwide pandemic (3) .

R4NFR6

AGL44440

Virus

Unconjugated

Primary Antibodies

Infectious Disease

Avian Influenza A H7N9 Neuraminidase antibody is affinity chromatography purified via peptide column.

1 mg/mL

Avian Influenza A H7N9 Neuraminidase Antibody is supplied in PBS containing 0.02% sodium azide.

None

Blue Ice

Avian Influenza A H7N9 Neuraminidase antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

IgG

Virus

Avian Influenza A H7N9 Neuraminidase antibody can be used for detection of Avian Influenza A H7N9 Neuraminidase by ELISA at 1 μ g/ml.

NA

Neuraminidase

Influenza A virus

Thompson WW, Shay DK, Weintraub, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186.

Alexander DJ. A review of avian influenza. Proceedings of the European Society for Veterinary Virology (ESVV) Symposium on Influenza Viruses of Wild and Domestic Animals. Vet. Microbiol. 2000; 74:3-13.

Wiwanitkit V. H7N9 influenza: the emerging infectious disease. N. Am. J. Med. Sci. 2013; 5:395-8.

Avian Influenza A H7N9 Neuraminidase Antibody:

ELISA

496493393

Liquid